AIM: Phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) are key enzymes in lipoprotein metabolism facilitating the transfer and exchange of cholesteryl esters, triglycerides and phospholipids between lipoproteins. In the study presented here, we investigated the influence of two hormones -the adipocyte-derived hormone leptin as well as insulin on the hepatic secretion of both, PLTP and CETP. METHODS: PLTP activity and CETP concentration -measured by exogenous substrate assay and enzyme-linked immunosorbent assay -were determined in supernatant of human hepatoma cell line HepG2 after single or combined exposure to leptin and insulin at physiological and supraphysiological concentrations, respectively. Messenger-RNA of PLTP and CETP was quantified by Northern blot analysis. RESULTS: Leptin suppressed PLTP activity and CETP-concentration by up to 33% and 23%, respectively. Insulin also suppressed PLTP activity by up to 11% and CETP-concentration by up to 16%. In combination, the two hormones had additive suppressive effects for both, PLTP activity and CETP-concentration. Northern blot analysis showed no difference in m-RNA levels after exposure to leptin or insulin. CONCLUSIONS: Leptin and insulin, both known to increase with body fat mass, suppress production of PLTP and CETP in HepG2 cells. When extrapolated to the in vivo situation, this suppressive effect may constitute a mechanism counteracting the potentially harmful action of lipid transfer proteins, particularly reduction of HDL-cholesterol, in conditions frequently associated with increased plasma triglyceride levels such as obesity and insulin resistance.
Introduction
Phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) are key factors in HDL metabolism and reverse cholesterol transport. 1 In vitro, PLTP facilitates the conversion of HDL particles to smaller and larger HDL particle species 2, 3 by transferring surface phospholipids between HDL particles leading to particle fusion and displacement of apoA-I from the particles' surface. 4, 5 One of the very important PLTP-mediated product HDL particles are the small lipid-poor pre-b-HDL which act as initial acceptors of unesterified cholesterol from cell surfaces. 6, 7 CETP catalyzes the transfer of cholesteryl esters (CE) from HDL to apoB-containg lipoproteins in exchange for triglycerides 8, 9 resulting in the conversion of larger to smaller particles and low HDL cholesterol levels. 10, 11 Thus, both PLTP and CETP stimulate several critical steps of reverse cholesterol transport.
Both PLTP and CETP activity are increased in obese subjects and correlated directly with the body mass index (BMI), 12, 13 suggesting that PLTP and CETP activity are affected by obesity and insulin resistance. 14 -16 In several clinical studies the influence of insulin infusion on lipid transfer protein activities was investigated with, however, partly conflicting results. 17 -21 In healthy subjects insulin infusion appeared not to change CETP activity in some studies, 18, 20, 21 while in others 13, 19 it decreased CETP activity. Similarily, for type 2 diabetic patients unchanged, 19, 20 decreased 17, 18 and accelerated CETP activities 22 have been reported. In hyperinsulinemic euglycemic clamp studies 19, 20 decreased PLTP activity after insulin infusion was reported in both, healthy and type 2 diabetic subjects. Similar results were found in a hyperglycemia-induced hyperinsulinemia study in healthy humans. 21 Very interesting observations with respect to obesity and insulin resistance affecting lipid transfer protein activity were reported by Riemens et al, 20 who found PLTP activity and CETP activity in healthy obese subjects increased when compared to non-obese healthy controls and also found that PLTP activity in type 2 diabetic obese patients increased when compared to type 2 diabetic non-obese subjects. These findings suggest factors other than insulin to be also involved in control of lipid transfer protein activities in obesity and insulin resistance. Leptin levels are increased in most obese subjects. 23 Leptin is a multifunctional cytokine 24 encoded by the ob gene 25 and expressed mainly in white adipose tissue. 25 Biologic activities of leptin are mediated through binding to the ob-receptor (R) and respective splicing variants expressed in hypothalamic and other tissues including kidney, lung, liver, bone marrow and testes. 26 -28 Leptin functions not only as a signal to the central nervous system of energy stores and food intake 24 but is involved also in the regulation of more or less related physiological functions such as neuroendocrine and immune system reponse to food deprivation, angiogenesis, the development and differentiation of hematopoietic cells, induction of onset of puberty and fetus and neonatal growth, 24 and glucose and insulin hoemeostasis. 24 Another function of leptin was recently described by Silver et al, 29 who reported that leptin influences apolipoprotein A-I and A-II metabolism in ob=ob mice.
In the present study we examined whether leptin affects lipid transfer proteins. For our experiments, we chose the human hepatoma cell line HepG2, known to express ob-R and one splice variant of ob-R 30 as well as the insulin 31 and IGF-I receptor. 32 HepG2 cells synthesize and secrete bile acids, lipoproteins in the VLDL, LDL and HDL ranges and a variety of plasma proteins including apolipoproteins B, E, A-I, A-II, A-IV, C-II, C-III, CETP and PLTP; although in partly different concentrations and relations when compared to human plasma. 33 -35 To prove possible agonistic or antagonistic effects of leptin and insulin, cells were exposed to both substances separately and together, respectively, and m-RNA levels and enzyme activity or mass of PLTP and CETP, respectively, were determined.
Methods

Cell culture
Human hepatoma cells HepG2 (ATCC, Manassas, VA, USA) were maintained at 37 C and at 5% CO 2 =95% air in RPMI 1640 medium (Biochrom KG, Berlin, Germany) supplemented with 10% fetal bovine serum (Life Technologies, Rockville, MD, USA) 2 mM L-glutamine (Biochrom KG) and 10 g=ml penicillin=streptomycin (Seromed, Berlin, Germany). Fresh medium was added every third day and cells were split at a ratio of 1:4 every 7 days. For experiments, cells were plated in 3.5 cm dishes (Falcon, Meylan Cedex, France) at a density of 5Â10 5 cells per plate. When cells were confluent (after 3 days) fresh medium without fetal bovine serum was added. Cells were incubated with leptin (recombinant human leptin (OB), R&D Systems, Wiesbaden-Nordenstadt, Germany) and insulin (recombinant human insulin, Sigma-Aldrich, St. Louis, MO, USA) for 3 -36 h. Supernatant was used for PLTP activity assay and CETP ELISA. Cells were lysed with 0.1 M NaOH and cell protein was determined. 36 
PLTP activity assay
The ability of cell supernatant to transfer 3 H-dipalmitoylphosphatidylcholine ( 3 H-PC) (NEN Life Science Products, Boston, MA, USA) from PC vesicles to HDL 3 was measured as described. 37 -39 Ten micromoles of L-a phosphatidylcholine (Sigma), 2 mCi 3 H-PC and 0.1 mmol of butylated hydroxytoluene (Sigma) were mixed, dried under N 2 , and resuspended in 1 ml of 150 mM NaCl, 10 mM Tris -HCl, 1 mM EDTA (pH 7.4). After probe-sonication lipid aggregates and titanium debris were removed by centrifugation. 3 H-PC vesicles were incubated with cell supernatant and HDL 3 (250 mg protein) prepared by rate-zonal ultracentrifugation 40 in a final volume of 400 ml of 150 mM NaCl, 10 mM TrisHCl, pH 7.4 at 37
C for 1 h. After incubation, vesicles were separated from HDL 3 by addition of 300 ml of a 500 mM NaCl, 215 mM MnCl 2 , 445 units=ml heparin solution, followed by centrifugation. The supernatant (500 ml) was counted in a LS 6500 Scintillation Counter (Beckman, Palo Alto, CA, USA). PLTP activity of cell supernatant was adjusted to protein content of cells and was linear up to 1 h. Addition of highly purified CETP, 41 or polyclonal anti-CETP-antibodies or polyclonal anti-hepatic lipase antibodies, respectively, did not influence PLTP activity measurements of cell supernatant. ApoA-I content in cell supernatant determined by semiquantitative Western Blot analysis using a monoclonal anti apoA-I antibody for detection (Anti-human apoA-I, ICN Biomedicals, Eschwege, Germany) and purified human apoA-I as standard (Apolipoprotein A-I, Sigma) was negligible compared to apoA-I content of HDL 3 used as phospholipid acceptor particles (data not shown).
CETP-ELISA CETP concentration in cell supernatant was determined by ELISA, as described previously, 42 using monoclonal anti-CETP-antibodies for capture and polyclonal anti-CETP antibodies for detection.
Reverse transcription (RT) and polymerase chain reaction (PCR) PLTP and CETP cDNA for Northern blot analysis was obtained by specific RT-PCR. Reverse transcription was performed from mRNA from HepG2 by Superscript II reverse transcriptase (Life Technologies) using a random hexanucleotide mix (Roche, Basel, Switzerland). PLTP cDNA PCR was performed with native Pfu Polymerase (Stratagene, La C for 3 min in a total volume of 20 ml, respectively. For CETP cDNA PCR F2 and R1 olignoucleotides were used, 43 while for PLTP cDNA PCR 5 0 -GGTACCATGAGTTCC-CAGGCTGCAAGATC-3 0 and 5 0 TCTAGAGAC AGCTGCTGTG GACGGTGT-3 0 primers were used, respectively. The specific PCR products were purified using NucleoSpin Extract (Macherey-Nagel, Düren, Germany).
RNA preparation and Northern analysis
Total RNA from HepG2 cells was extracted using RNAClean TM System (Dipro, Wiener Neudorf, Austria). Ten micrograms of total RNA were separated by denaturating agarose-electrophoresis, blotted on a nylon membrane (Duralon-UV membrane, Stratagene) and hybridized with radiolabeled PLTP, CETP or GAPDH cDNA, respectively. Amount of PLTP, CETP and GAPDH mRNA was measured by Phospho Imager (Cyclone, Packard, Meriden, CT, USA).
Other analytical procedures Albumin concentration in supernatant was determined by ELISA (human Albumin ELISA, Immundiagnostik, Bensheim, Germany).
Statistical analysis
Data are expressed as means AE s.d. Statistical differences between means were estimated by unpaired t-test. Statistical significance was inferred at a two-tailed P-value < 0.05. Oneway ANOVA analysis was used to test for statistical difference between means of PLTP activity and CETP concentration of either leptin-or insulin-treated cells and cells exposed to both hormones together. SPSS for Windows (Version 8.0) was used for statistical analyses.
Results
PLTP-activities and CETP concentrations were measured after 12, 18, 24 and 36 h in supernatant of untreated HepG2 cells and HepG2 cells exposed to leptin at the physiological concentration of 625 pmol=l and at supraphysiological concentrations of 6.25 nmol=l, 62.5 nmol=l and 625 nmol=l and=or insulin at the physiological concentration of 61.5 pmol=l and the supraphysiological concentrations of 615 pmol=l, 6.15 nmol=l and 61.5 nmol=l, respectively. Protein content of cells did not differ between stimulated and untreated cells.
PLTP activity
Dose-dependent suppressive effects of leptin on PLTP activity in cell supernatant of HepG2 cells are shown in Figure 1A . After a 36 h exposure to leptin at the highest indicated concentration of 625 nmol=l, PLTP activity was decreased by 33.1 AE 1.2% (P ¼ 0.01, n ¼ 5).
Dose-depending suppressive effects of insulin on PLTP activity are shown in Figure 1B . After 36 h exposure to insulin at the highest indicated concentration of 61.5 nmol=l, PLTP activity in supernatant was decreased by 10.5 AE 1.8% (P < 0.01, n ¼ 5).
Exposure of HepG2 cells to leptin and insulin together led to a significant decrease of PLTP activity at any indicated physiological and supraphysiological concentration after 24 and 36 h (P < 0.01) which was more pronounced than that obtained with leptin or insulin alone at the same concentration after 24 and 36 h, respectively (P < 0.01) ( Figure 1C ).
CETP-concentration
Effects of leptin and=or insulin on CETP concentration in supernatant of HepG2 cells are shown in Figure 2 . No significant changes in CETP concentrations were found with exposure times to leptin of up to 24 h. However, exposure to leptin for 36 h decreased CETP mass in supernatant in a dose-dependent fashion of up to 23% (P < 0.01, n ¼ 5; Figure 2A ). Exposure to insulin for 36 h at concentrations of 615 pmol=l, 6.15 nmol=l and 61.5 nmol=l caused a significant decrease of CETP mass by up to 16% (P < 0.01, n ¼ 5; Figure 2B ). When HepG2 cells were exposed to both, leptin and insulin, the decrease of CETP mass in supernatant was more pronounced than that obtained with leptin at concentrations between 6.25 nmol=l and 625 nmol=l and insulin at concentrations at 615 pmol=l and 61.5 nmol=l after 36 h (P < 0.01; Figure 2C ).
To exclude a general effect of leptin or insulin on protein secretory rate of HepG2 cells, albumin secretion was determined after exposure to leptin and=or insulin. Albumin secretion in supernatant was not significantly influenced by leptin; in the presence of leptin (625 nmol=l leptin) 256 AE 9 mg=g cell protein=h albumin were found and in the absence of leptin 269 AE 8 mg=g cell protein=h albumin were obtained. The same was true for insulin (61.5 nmol=l insulin): 273 AE 20 mg=g cell protein=h albumin were found with insulin and 256 AE 9 mg=g cell protein=h albumin in the absence of insulin.
Northern analysis
Messenger (m)-RNA was isolated after incubation times of 3, 6, 12, 24 and 36 h in untreated cells and in cells exposed to leptin at concentrations of 625 pmol=l, 6.25 nmol=l, 62.5 nmol=l and 625 nmol=l or insulin at concentrations of 61.5 pmol=l, 615 pmol=l, 6.15 nmol=l and 61.5 nmol=l, respectively. Northern blot analysis showed no difference in m-RNA levels of PLTP or CETP after leptin or insulin 
Discussion
High HDL levels are considered protective against coronary heart disease, stroke and peripheral vascular disease. 44 -47 The lipid transfer proteins are key proteins in HDL metabolism in that PLTP transfers phospholipids and CETP -in addition to phospholipids -transfers CE from HDL to apoB-containing lipoproteins in exchange for TG. The role of PLTP in lipoprotein metabolism, especially HDL metabolism, was shown in PLTP-knock out mice and in mice overexpressing PLTP. Both, overexpression of PLTP 37, 48, 49 and targeted mutation of PLTP 50 led to a dramatic reduction of HDL-cholesterol (HDL-C) in plasma, although through different mechanisms; it was hypothesized 50 that PLTP knock-out reduced HDL due to decreased transfer of surface components from TG-rich lipoproteins into HDL and altered stability of HDL particles. Overexpression of PLTP, it was hypothesized, 49 accelerates HDL catabolism leading to a decrease of HDL levels. In the latter situation, despite low HDL levels, increased formation of pre-ß-HDL was observed 49 as was enhanced efficiency of plasma in preventing the accumulation of intracellular cholesterol, 49 both effects potentially promoting an antiatherogenic situation.
Data about the role of CETP in atherogenesis are controversial. CETP deficiency 43, 51, 52 has been described as a possible genetic reason for high HDL levels considered protective of ischemic heart disease. Other studies suggested that higher HDL levels due to mutations in CETP are associated with an increased risk from coronary heart disease. 53, 54 The aim of the study presented here was to investigate whether hepatic secretion of PLTP and CETP is influenced by leptin and insulin, two hormones characteristically elevated in states of obesity and insulin resistance. For our studies we chose HepG2 cells in culture because of the central role of the liver in lipoprotein metabolism and reverse cholesterol transport and because cell culture systems afford the opportunity to directly observe effects of leptin and insulin. HepG2 cells have been well established as resource for metabolic studies because many functions, but not all, functions in lipoprotein metabolism attribute to normal human hepatocytes. Decreases of PLTP activity were considered significant at concentrations of 6.25 nmol=l leptin þ 615 pmol=l insulin (P ¼ 0.04), 62.5 nmol=l leptin AE 6.15 nmol=l insulin (P ¼ 0.02) and 625 nmol=l leptin þ 61.5 nmol=l insulin (P ¼ 0.04) after an 18 h exposure and at all tested concentrations after a 24 and 36 h exposure (P < 0.01), respectively. The suppressive effects were statistically more pronounced at all tested concentrations after 24 and 36 h exposure than the ones obtained with leptin or insulin at the same concentration alone (P < 0.01). Data are means AE s.d. of five independent experiments each performed in duplicate.
Leptin and insulin on lipid transfer proteins S Kaser et al
Our data show that leptin directly affects PLTP activity in supernatant of HepG2 cells. PLTP activity was decreased at both, physiological and supraphysiological leptin levels. Albumin concentrations in supernatant were not influenced by leptin excluding a general effect of leptin on protein secretory rate. Messenger RNA levels of PLTP were not influenced by leptin, suggesting a post-translational effect on lipid transfer proteins. These data are consistent with recent reports on leptin deficient mice (ob=ob) displaying increased PLTP activity but unchanged PLTP m-RNA. 29 What would be the consequence of leptin-mediated decreased PLTP activity? In vitro, decreased PLTP activity leads to reduced fusion of HDL particles and reduced dissociation of apoA-I=phospholipid complexes 5 believed to be pre-b-HDL crucial as initial acceptors for cellular cholesterol. 7 With egress of cellular cholesterol to plasma lipoproteins partially blocked, decreased PLTP activity may very well reduce reverse cholesterol transport. In our experiments, the Leptin and insulin on lipid transfer proteins S Kaser et al suppressive effect of leptin was not restricted to PLTP but was found for CETP also. These two effects on PLTP and CETP would complement each other resulting in what could be viewed as an overall negative effect of leptin on reverse cholesterol transport from peripheral tissues to the liver. However, this effect could very well be desireable in obesity and type 2 diabetes; in both conditions plasma triglyceride levels are frequently increased accompanied with CETPmediated loss of HDL-cholesterol. 10, 11 In both situations, leptin and insulin levels are high reducing PLTP and CETP levels and consequently loss of HDL cholesterol.
We interpret our results to suggest that adipose tissue holds an important role for regulating lipoprotein metabolism, particularly in settings where adipose tissue mass is enlarged; adipose tissue not only produces leptin, constituting the effector in the hierarchy laid down herein, but also the 'affected players' CETP 55, 56 and PLTP. 57 Leptin-and insulin-mediated suppression of lipid transfer proteins in the liver might compensate for the increased secretion of PLTP and CETP by the augmented adipocyte mass of obesity and insulin resistance.
Our observation that effects of insulin and leptin on PLTP and CETP were additive are in keeping with the fact that several interactions between insulin and leptin have already been described and are, at least, partly consistent with different signaling pathways for each hormone. 30 In conclusion, our results suggest a potentially novel mechanism by which adipose tissue modulates lipoprotein metabolism and reverse cholesterol transport. This process may serve to balance increased secretion of lipid transfer proteins by adipocytes in clinically important settings of obesity and insulin resistance.
